Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
AVM Biotechnology Inc
New York Medical College
BeOne Medicines
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Verismo Therapeutics
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
AstraZeneca
Alliance Foundation Trials, LLC.
Adicet Therapeutics
Dana-Farber Cancer Institute
Calibr, a division of Scripps Research
Gilead Sciences
AstraZeneca
Alliance for Clinical Trials in Oncology
City of Hope Medical Center
British Columbia Cancer Agency
Novartis
City of Hope Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Washington University School of Medicine
Vironexis Biotherapeutics Inc.
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
AbbVie
Memorial Sloan Kettering Cancer Center
AstraZeneca
Canadian Cancer Trials Group
Hackensack Meridian Health
Ohio State University Comprehensive Cancer Center
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
BeOne Medicines
Gilead Sciences
Cellectar Biosciences, Inc.
MEI Pharma, Inc.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The Lymphoma Academic Research Organisation
Massachusetts General Hospital
Galapagos NV